JP2023536509A5 - - Google Patents

Info

Publication number
JP2023536509A5
JP2023536509A5 JP2023508083A JP2023508083A JP2023536509A5 JP 2023536509 A5 JP2023536509 A5 JP 2023536509A5 JP 2023508083 A JP2023508083 A JP 2023508083A JP 2023508083 A JP2023508083 A JP 2023508083A JP 2023536509 A5 JP2023536509 A5 JP 2023536509A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
trifluoromethyl
bis
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023508083A
Other languages
English (en)
Japanese (ja)
Other versions
JP7877294B2 (ja
JP2023536509A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/110506 external-priority patent/WO2022028459A1/en
Publication of JP2023536509A publication Critical patent/JP2023536509A/ja
Publication of JP2023536509A5 publication Critical patent/JP2023536509A5/ja
Application granted granted Critical
Publication of JP7877294B2 publication Critical patent/JP7877294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023508083A 2020-08-05 2021-08-04 アクアポリン阻害剤の医薬組成物およびその製造方法 Active JP7877294B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010779964 2020-08-05
CN202010779964.6 2020-08-05
PCT/CN2021/110506 WO2022028459A1 (en) 2020-08-05 2021-08-04 Pharmaceutical composition of aquaporin inhibitor and preparation method thereof

Publications (3)

Publication Number Publication Date
JP2023536509A JP2023536509A (ja) 2023-08-25
JP2023536509A5 true JP2023536509A5 (cg-RX-API-DMAC10.html) 2024-08-06
JP7877294B2 JP7877294B2 (ja) 2026-06-22

Family

ID=80120008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023508083A Active JP7877294B2 (ja) 2020-08-05 2021-08-04 アクアポリン阻害剤の医薬組成物およびその製造方法

Country Status (12)

Country Link
US (1) US20230293556A1 (cg-RX-API-DMAC10.html)
EP (1) EP4192442A4 (cg-RX-API-DMAC10.html)
JP (1) JP7877294B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230137284A (cg-RX-API-DMAC10.html)
CN (1) CN117337182A (cg-RX-API-DMAC10.html)
AU (1) AU2021323181A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023002129A2 (cg-RX-API-DMAC10.html)
CA (1) CA3187716A1 (cg-RX-API-DMAC10.html)
IL (1) IL300341A (cg-RX-API-DMAC10.html)
MX (1) MX2023001493A (cg-RX-API-DMAC10.html)
TW (1) TW202228714A (cg-RX-API-DMAC10.html)
WO (1) WO2022028459A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
AU2017261828B2 (en) 2016-05-13 2023-04-13 Aeromics, Inc. Crystals
WO2024208207A1 (zh) * 2023-04-03 2024-10-10 拜西欧斯(北京)生物技术有限公司 一种双取代萘化合物及其药物组合物和用途
WO2025075479A1 (ko) * 2023-10-04 2025-04-10 이화여자대학교 산학협력단 아쿠아포린 4 억제제의 심방세동 치료 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7626042B2 (en) * 2002-06-06 2009-12-01 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
US9316633B2 (en) * 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
SG11201604477SA (en) * 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
AU2017261828B2 (en) * 2016-05-13 2023-04-13 Aeromics, Inc. Crystals

Similar Documents

Publication Publication Date Title
JP7475395B2 (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
CA2814371C (en) Use of malononitrilamides in neuropathic pain
KR20120013404A (ko) 화상 치료 조성물 및 방법
JP2023512763A5 (cg-RX-API-DMAC10.html)
JP2022533981A5 (cg-RX-API-DMAC10.html)
KR20200036920A (ko) 행동 변경 치료 방법
JP2025142200A (ja) ダプトマイシン製剤
JP7224687B2 (ja) 局所注射用組成物
JP2023536509A (ja) アクアポリン阻害剤の医薬組成物およびその製造方法
DD298478A5 (de) Verwendung eines heteroaryl-3-oxo-propannitrilderivats und pharmazeutisches praeparat zur behandlung von auroimmunerkrankungen
JP2022507838A (ja) エドキサバンを含む薬学的製剤およびその製造方法
JP2025134747A5 (cg-RX-API-DMAC10.html)
US20240382455A1 (en) Composition containing 1h-pyrazole-3-amide-based compound derivative for prevention or treatment of fibrosis
JP2019516722A (ja) 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用
JP2021501739A (ja) ホスホコリン誘導体を含有する脂肪分解組成物
WO2011149012A1 (ja) イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の予防または治療方法、イソキノリンスルホニル誘導体またはその医薬的に許容される塩、ならびにその使用
JP2023501397A (ja) 肥満細胞疾患および好酸球性障害の治療
WO2024139978A1 (zh) Vofopitant用于治疗肺纤维化的用途
EA008145B1 (ru) Инъецируемая галеновая форма флупиртина
CN111494370B (zh) Pyr3在制备保护肝损伤的药物中的应用
IL318683A (en) Novel salts and crystals
CN107496426A (zh) 含伊马替尼或其药学上可接受的盐作为有效成分的用于治疗或预防血管渗透性疾病的组合物
JP6907174B2 (ja) アミロイド線維形成の抑制又は阻害剤
AU2016364380B2 (en) Formulations for intravenous injection of danirixin
KR102832710B1 (ko) 당뇨병 또는 당뇨합병증의 치료를 위한 4-헥실레조르시놀의 용도